Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-09-24
2000-12-05
Aulakh, Charamjit S.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546 26, 546 28, 546 31, 546 35, 546 36, A61K 31485, C07D48910
Patent
active
061567620
DESCRIPTION:
BRIEF SUMMARY
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a 371 of PCT/JP98/00092 filed Jan. 13, 1998 now WO98/31684 and claims priority of Japanese Application No. 5829, filed Jan. 16, 1997.
TECHNICAL FIELD
The present invention relates to indolomorphinan derivatives or pharmacologically acceptable acid addition salts thereof, and an agent for curing and preventing cerebral disorders comprising the derivatives or salts thereof, and particularly to a medicine useful for ameliorating various cerebral diseases and aftereffects thereof, and preventing the recurrence thereof.
BACKGROUND ART
In recent years, diseases in the cerebral region such as various cerebrovascular diseases have increased with the arrival of the aging society. Cerebrovascular diseases are possibly caused by aging, hypertension, arterial sclerosis, hyperlipidemia, and the like, and are generally referred to as "cerebral stroke". In a broad sense, cerebral vascular diseases possibly include functional disorders of the brain due to head trauma.
Cerebral stroke is roughly classified into ischemic (infarcted) diseases and hemorrhagic diseases. Examples of the former include cerebral infarction (cerebral thrombosis, cerebral embolism(, and the like, and examples of the latter include cerebral hemorrhage, subarachnoid hemorrhage, and the like. In these diseases, the blood flow is clogged due to a cerebrovascular disorder, and thus glucose and oxygen, which are energy sources of the action of the cerebral nerve cells, are insufficiently supplied, resulting in various damage of the nerve cells. These diseases are fundamentally caused by death of the cerebral nerve cells of a damage area and the periphery thereof. Such cerebrovascular diseases cause occurrence of various aftereffects such as cerebrovascular dementia, which are critical medical and social problems at present.
Medicines which have been developed as agents for curing such cerebrovascular diseases in Japan are mainly used for ameliorating aftereffects such as psychoneurosis and the like, and main medicines have the function to increase the amount of the blood flow to the brain to promote the supply of glucose and oxygen to an ischemic area. From the viewpoint of the functional mechanism, these medicines are expressed by vague terms such as medicines for ameliorating the cerebral blood flow, medicines for activating cerebral metabolism, and medicines for ameliorating cerebral function. However, almost all of these medicines are effective in ameliorating marginal symptoms such as volition disorders, affective disorders, behavioral abnormality, and the like, while the activity to the nucleus symptoms of dementia such as memory disorders and the like is considered as doubtful. Also some anti cerebral edema agents, antithrombotic agents, and thrombolytic agents are clinically used, particularly, in the acute stage of a cerebrovascular disease. These agents also have no direct action on the cerebral nerve cells, but are used only for symptomatic therapy. In any case, the above present medicines have substantially no effect on damage of the cerebral nerve cells in cerebrovascular diseases, and have no action to inhibit directly the death of the cerebral nerve cells.
As described above, there is now no medicine effective against damage of the cerebral nerve cells which are fundamental causes of cerebrovascular diseases. It is known that the degree of such damage has correlation to the ischemia time the cerebral blood flow is clogged, and a long ischemia time causes organic damage to the cerebral nerve cells which are not ameliorated even by recovery of the blood flow. For such cerebrovascular disorders, it is important to cure the disorders in the acute stage within 24 hours from the occurrence of the disease. Therefore, there is now demand for developing, as early as possible, a medicine which has the effect of securely protecting damages of the cerebral nerve cells and which is easy to use.
In addition to such cerebrovascular disorders, an increase in cerebral neurodegenerative dise
REFERENCES:
patent: 5852030 (1998-12-01), Nagase et al.
Hirokawa Junichi
Imamura Yoshifumi
Matsuda Susumu
Miyauchi Yasushi
Nagase Hiroshi
Aulakh Charamjit S.
Miller Austin R.
Toray Industries Inc.
LandOfFree
Indolomorphinan derivative and agent for curing and preventing c does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indolomorphinan derivative and agent for curing and preventing c, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indolomorphinan derivative and agent for curing and preventing c will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-962051